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Summary
Background Innovative prevention strategies for HIV-1 transmission are urgently needed. PRO2000 vaginal gel was 
eﬃ  cacious against HIV-1 transmission in studies in macaques; we aimed to assess eﬃ  cacy and safety of 2% and 0·5% 
PRO2000 gels against vaginal HIV-1 transmission in women in sub-Saharan Africa.
Methods Microbicides Development Programme 301 was a phase 3, randomised, double-blind, parallel-group trial, 
undertaken at 13 clinics in South Africa, Tanzania, Uganda, and Zambia. We randomly assigned sexually active women, 
aged 18 years or older (≥16 years in Tanzania and Uganda) without HIV-1 infection in a 1:1:1 ratio to 2% PRO2000, 0·5% 
PRO2000, or placebo gel groups for 52 weeks (up to 104 weeks in Uganda). Randomisation was done by computerised 
random number generator. Investigators and participants were masked to group assignment. The primary eﬃ  cacy 
outcome was incidence of HIV-1 infection before week 52, which was censored for pregnancy and excluded participants 
without HIV-1 follow-up data or with HIV-1 infection at enrolment. HIV-1 status was established by rapid tests or ELISA 
at screening at 12 weeks, 24 weeks, 40 weeks, and 52 weeks, and conﬁ rmed in a central reference laboratory. The primary 
safety endpoint was an adverse event of grade 3 or worse. Use of 2% PRO2000 gel was discontinued on Feb 14, 2008, on 
the recommendation of the Independent Data Monitoring Committee because of low probability of beneﬁ t. This trial is 
registered at http://isrctn.org, number ISRCTN 64716212.
Findings We enrolled 9385 of 15 818 women screened. 2591 (95%) of 2734 participants enrolled to the 2% PRO2000 
group, 3156 (95%) of 3326 in the 0·5% PRO2000 group, and 3112 (94%) of 3325 in the placebo group were included in 
the primary eﬃ  cacy analysis. Mean reported gel use at last sex act was 89% (95% CI 86–91). HIV-1 incidence was much 
the same between groups at study end (incidence per 100 woman-years was 4·5 [95% CI 3·8–5·4] for 0·5% PRO2000 vs 
4·3 [3·6–5·2] for placebo, hazard ratio 1·05 [0·82–1·34], p=0·71), and at discontinuation (4·7 [3·8–5·8] for 2% PRO2000 
gel, 3·9 [3·0–4·9] for 0·5% PRO2000 gel, and 3·9 [3·1–5·0] for placebo gel). Incidence of the primary safety endpoint at 
study end was 4·6 per 100 woman-years (95% CI 3·9–5·4) in the 0·5% PRO2000 group and 3·9 (3·2–4·6) in the 
placebo group; and was 4·5 (3·7–5·5) in the 2% PRO2000 group at discontinuation.
Interpretation Although safe, 0·5% PRO2000 and 2% PRO2000 are not eﬃ  cacious against vaginal HIV-1 transmission 
and are not indicated for this use.
Funding UK Department for International Development, UK Medical Research Council, European and Developing 
Countries Clinical Trials Partnership, International Partnership for Microbicides, and Endo Pharmaceu ticals Solutions.
Introduction
With an estimated 1·9 million new HIV-1 infections in 
sub-Saharan Africa in 2008, innovative strategies for 
prevention are urgently needed.1 Women in Africa are 
disproportionately aﬀ ected by HIV-1 and many are unable 
or unwilling to negotiate condom use, want to conceive, 
or both. Vaginal microbicides are a potential method for 
prevention of HIV-1 transmission that is controlled by 
the woman. After several disappointing trials,2–5 the 
phase 2/2b trial, HPTN035,6 reported that the vaginal 
microbicide 0·5% PRO2000 led to a non-signiﬁ cant 
reduction in HIV-1 incidence of 30% (hazard ratio 0·7, 
95% CI 0·46–1·08, p=0·10) compared with placebo gel.
We report the Microbicides Development Programme 
(MDP) 301 trial, which assessed the eﬃ  cacy and safety 
of 0·5% and 2% PRO2000 gels compared with 
hydroxyethylcellulose placebo gel7 for prevention of 
vaginally acquired HIV-1 infection. This trial was done 
by the MDP, a collaborative partnership of institutions 
in Africa and Europe. PRO2000 is a synthetic 
naphthalene sulphonate polymer of around 5 kDa 
molecular weight, with antiviral activity against HIV-1 
and other sexually transmitted infections as shown in 
laboratory studies and in studies in animals, 
including macaque challenge experiments with X4 
and R5 simian –human immunodeﬁ ciency virus,8–13 and 
a favourable safety proﬁ le in phase 1/2 clinical trials.14–17 
We aimed to assess the eﬃ  cacy and safety of PRO2000 
gels for prevention of vaginal HIV-1 transmission in 
sub-Saharan Africa.
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Methods
Participants and design
MDP301 was a phase 3, randomised, double-blind, parallel-
group trial. Full details of trial design, sample size, research 
sites, study populations, study conduct including the 
randomisation and masking, and data underpinning the 
sample size assumptions, have been reported.18 We did a 
social science substudy to assess accuracy of behavioural 
and adherence data, which is described in detail 
elsewhere.19,20
Participants were enrolled at 13 clinics, which were 
managed by six research centres, in Africa (three in South 
Africa, one in Tanzania, one in Uganda, and one in 
Zambia). Eligible women were 18 years or older (≥16 years 
in Tanzania and Uganda); did not have HIV-1 infection at 
screening and were willing to be tested for HIV-1 infection 
and receive the result; were willing to have regular 
speculum examinations and urinary pregnancy tests; were 
willing to use gel as instructed; were likely to be sexually 
active; were willing to receive health education about 
condoms; and were willing and able to give informed 
consent. Women were not eligible if they were unable or 
unwilling to provide a reliable method of contact; were 
likely to move out of the area within 12 months; were likely 
to have sex more than 14 times a week on a regular basis 
(a regulatory requirement was that no more than 
60 applicators were to be dispensed at every 4 weekly visit); 
used spermicides regularly; were pregnant or within 
6 weeks post partum; had a severe clinical or laboratory 
abnormality; needed referral for assessment of a suspicious 
cervical lesion; had received treatment to the cervix or 
other gynaecological procedure within 30 days of 
enrolment; were allergic to latex; or were participating or 
had participated in another clinical trial that was likely to 
aﬀ ect the primary eﬃ  cacy endpoint within 30 days before 
enrolment.
The protocol was approved by local and national ethics 
committees, in all participating countries and in the UK. 
Authorisation was obtained from the national regulatory 
authority in all participating countries and the US Food 
and Drug Administration. Participants indicated their 
consent by signature or witnessed thumbprint.
Randomisation and masking
Participants were randomly assigned in a 1:1:1 ratio to 2% 
PRO2000, 0·5% PRO2000, or placebo groups. Participants 
were randomly assigned on the basis of lists that were 
created with randomised permuted blocks of varying size, 
for each of the 13 clinics, by an independent statistician 
with a computerised random number generator, 
containing unique trial numbers matched to nine sets of 
study product codes. Site pharmacists dispensed gel in 
identical applicators on the basis of the trial number and 
the assigned study product codes on the clinic 
randomisation list. No other site personnel had access to 
the list. Success of masking was not formally addressed. At 
enrolment, women were assigned a unique trial number 
selected sequentially from the clinic trial register. Only 
statisticians responsible for preparation of the Independent 
Data Monitoring Committee reports and essential 
manufacturing and distribution staﬀ  had access to the list 
matching study product codes to gel.
Procedures
Visits were scheduled every 4 weeks for 52 weeks (up to 
104 weeks in Uganda to provide long-term safety data). Gel 
was dispensed in packs of ten preﬁ lled single dose 
applicators (maximum of 60 applicators in ten packs per 
visit), after a negative urinary pregnancy test. Women were 
instructed to apply gel within an hour before sexual 
intercourse. They were counselled to use condoms during 
all sex acts and received unrestricted supplies of free 
condoms at the research clinics. Gel supply was interrupted 
if a participant had a positive pregnancy test and could be 
resumed after a negative pregnancy test. At every 4 week 
visit, women were asked about gel and condom use at the 
most recent sex act and returned used and unused 
applicators, which were were counted and recorded for 
assessments of adherence.
HIV-1 status was assessed at 12 weeks, 24 weeks, 
40 weeks, and 52 weeks (up to 104 weeks in Uganda) and 
when gel supply was interrupted or discontinued because 
of a positive pregnancy test. A clinical interview and pelvic 
examination to report genital and non-genital adverse 
events were also done at these visits, at week 4, and if a 
pregnancy was diagnosed. Adverse events were deﬁ ned by 
ICH guidelines and MedDRA coded. Solicited genital 
symptoms and signs were non-menstrual bleeding, genital 
sores or ulcers, genital discomfort (itching, burning, or 
dryness), and external or internal epithelial disruption, 
genital erythema, and genital oedema.
Routine haematology and biochemistry tests were done 
for the ﬁ rst 500 participants enrolled in centres in Durban 
and Johannesburg, South Africa, and all 840 participants 
in Uganda at screening and at 12 weeks, 24 weeks, and 
52 weeks (and 104 weeks or at ﬁ nal visit in Uganda). 
Additionally, a plasma sample was obtained from these 
participants at the ﬁ nal visit for PRO2000 analysis.
To conﬁ rm HIV-1 status, serum was obtained up to 
6 weeks before enrolment, at enrolment, and then at 
weeks 4, 12, 24, 40, and 52 (and week 72 and 104 in Uganda); 
buﬀ y coat was obtained at enrolment, and at weeks 24, 40, 
and 52 (and week 104 in Uganda). The HIV-1 testing 
algorithm comprised parallel HIV-1 rapid tests at the 
clinics, with discordant or positive tests after enrolment 
triggering ELISA testing at local laboratories and 
conﬁ rmation at a central laboratory in South Africa. A 
second serum sample was obtained at the subsequent visit 
after a ﬁ rst positive rapid test result. The central laboratory 
analysed samples from the visit at which a positive rapid 
test result was obtained and from all previous visits at 
which samples were obtained. This analysis allowed 
detection of seroconversion to be established as at or 
before enrolment.
For the trial protocol see http://
www.mdp.mrc.ac.uk/
publications_documents/
MDP301_2.1_FINAL.pdf
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The algorithm was designed to conﬁ rm HIV-1 
infection on the basis of two separate samples, with two 
diﬀ erent methods of diagnosis. Serum samples were 
tested for HIV-1 antibodies with Abbott AxSYM HIV 
Ag/Ab Combo (fourth-generation ELISA; Wiesbaden, 
Germany), Bio-Rad Genetic Systems HIV-1 ELISA 
(third-generation ELISA; Redmond, WA, USA), and 
Genetic Systems HIV-1 Western Blot (Redmond, WA, 
USA) assays. We used Biomerieux Vironostika HIV-1 
antigen ELISA (Boxtel, Netherlands) as a conﬁ rmatory 
assay for p24 testing. Buﬀ y coat samples were tested 
with the Roche qualitative DNA PCR Version 1.5 assay 
(Roche Diagnostic Systems, Branchburg, NJ, USA). The 
Roche COBAS Amplicor HIV-1 Monitor (Roche 
Diagnostic Systems) was used for the detection of HIV-1 
RNA if the buﬀ y coat specimen was not satisfactory.
Endpoints
The primary eﬃ  cacy endpoint was HIV-1 infection, 
conﬁ rmed by the central reference laboratory, in 
participants who were conﬁ rmed without HIV-1 
infection at enrolment. Secondary eﬃ  cacy endpoints 
were acquisition of herpes simplex virus type 2 (HSV-2) 
infection by participants who were HSV-2 seronegative 
at enrolment, which was established serologically and 
conﬁ rmed by the central laboratory at 40 weeks and 
52 weeks; or presence of Neisseria gonorrhoeae or 
Chlamydia trachomatis, which was established by a 
positive nucleic acid ampliﬁ cation assay at 24 weeks.
The primary safety endpoint was a grade 3 (severe) or 
worse clinical or laboratory adverse event, irrespective 
of relation to trial gel. Secondary safety endpoints were 
reported local toxic eﬀ ects (any grade of genital itching, 
burning, internal epithelial disruption, internal 
erythema, or internal oedema) and systemic toxic eﬀ ects 
(any increase in grade from baseline in routine 
laboratory variables). We systematically assessed these 
outcomes because of a probable or known association 
with PRO2000 when administered vaginally or 
systemically in previous trials.21,22
The primary eﬃ  cacy outcome was originally designed 
to be measured at 40 weeks, which changed to 52 weeks 
after commencement of the trial.18
Discontinuation
The MDP301 trial protocol stated that the Independent 
Data Monitoring Committee could recommend early 
termination of the trial “if there was proof beyond 
reasonable doubt that one of the trial interventions is 
clearly indicated or clearly contraindicated in terms of a 
net diﬀ erence in seroincidence or adverse events”. The 
2% PRO2000 gel was discontinued on Feb 14, 2008, 
after a review by the committee on Feb 8, 2008 of 
available data up to Jan 15, 2008. The committee advised 
there was little chance of 2% PRO2000 gel showing 
beneﬁ t given the planned sample size and postulated 
eﬀ ect size. However, the conditional power for 
signiﬁ cant beneﬁ t from the 0·5% PRO2000 dose, based 
on the original sample size assumptions, was suﬃ  ciently 
high to warrant trial continuation. We report data for 
the 0·5% PRO2000 and placebo groups to study end, 
and data for the 0·5% PRO2000, 2% PRO2000, and 
placebo groups with data up until discontinuation on 
Feb 14, 2008.
Statistical analysis
MDP301 was designed with 80% power to detect a 35% 
reduction in HIV-1 incidence (90% for a 40% reduction), 
assuming an incidence in the placebo group of 4·0 per 
100 woman-years. The assumptions made for incidence 
and loss to follow-up (we predicted 3300 participants 
would be needed per group, assuming 20% loss of 
woman-years of follow-up) were derived from data in 
previous cohort studies.18
The primary eﬃ  cacy analysis comprised all enrolled 
participants, excluding those with HIV-1 infection at 
enrolment, those without follow-up data for HIV 
infection, and with censoring at 52 weeks (plus 6 week 
window for ﬁ nal visit) and while gel use was discontinued 
Figure 1: Trial proﬁ le
*1564 participants were in follow-up at Feb 14, 2008. 
15 818 women screened
9385 enrolled
2734 assigned to 2%
PRO2000 group
Follow up*
47 withdrawals
11 lost to follow-up
68 discontinued gel use
84 interrupted gel use
143 excluded
17 HIV-1 infections at
enrolment
126 No HIV-1 follow-up
data
2591 included in primary
eﬃcacy analysis 
3156 included in primary
eﬃcacy analysis 
3112 included in primary
eﬃcacy analysis 
170 excluded
27 HIV-1 infections at
enrolment
143 No HIV-1 follow-up
         data
213 excluded
25 HIV-1 infections at
enrolment
188 No HIV-1 follow-up
         data
Follow up
121 withdrawals
288 lost to follow-up
100 discontinued gel use
229 interrupted gel use
Follow up
118 withdrawals
352 lost to follow-up
110 discontinued gel use
238 interrupted gel use
3326 assigned to 0·5%
PRO2000 group
3325 assigned to
placebo group
6433 not eligible
4766 did not meet inclusion
criteria at screening
(8 returned and were
re-screened)
1063 did not return
after screening
593 did not meet inclusion
criteria at enrolment
19 enrolled twice (second
allocated number
excluded)
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because of pregnancy. For women who did not have 
HIV-1 infection when gel use was resumed after 
pregnancy, additional time was added to the woman-
years of follow-up for the primary eﬃ  cacy analysis.
A second eﬃ  cacy analysis was done with the same 
criteria as the primary eﬃ  cacy analysis, but without 
censoring for pregnancy and using all follow-up data. 
We assessed secondary eﬃ  cacy endpoints with two 
further analyses, censoring at 24 and 40 weeks 
(plus 4-week window) from enrolment, excluding those 
with HIV-1 infection at enrolment and censoring for 
pregnancy.
We did two planned subgroup analyses of patients, 
including tests for interaction. One subgroup analysis 
was stratiﬁ ed by research centre and one was done with 
postrandomisation data and categorised women 
according to the consistency of gel use, with the 
expectation that eﬃ  cacy against HIV-1 transmission 
would be greater in consistent users than it was in 
sporadic users. Gel use was predeﬁ ned as consistent if 
women reported use during the last sex act at 12 (92%) 
or more of 13 visits, or at least 92% of visits attended if 
fewer than 13; returned at least one used applicator to 
support their answer when appropriate; and attended at 
least seven of the expected 13 visits (unless they became 
pregnant or were infected with HIV-1 during 
follow-up).
In patients with HIV-1 seroconversion, the date of 
detection of HIV-1 infection was established by an 
endpoint committee. Woman-years of observation were 
censored at the date of seroconversion, estimated by the 
midpoint between the last negative test and date of 
2% PRO2000* (n=2734) 0·5% PRO2000 (n=3326) Placebo (n=3325)
Demographic
Age (years)
15–24 1022/2734 (37%) 1249/3326 (38%) 1267/3324 (38%)
25–34 955/2734 (35%) 1076/3326 (32%) 1096/3324 (33%)
35–44 532/2734 (19%) 723/3326 (22%) 702/3324 (21%)
≥45 225/2734 (8%) 278/3326 (8%) 259/3324 (8%)
Education
None 177/2734 (6%) 240/3326 (7%) 233/3324 (7%)
Primary 1927/2734 (70%) 2309/3326 (69%) 2271/3324 (68%)
Secondary or higher 630/2734 (23%) 777/3326 (23%) 820/3324 (25%)
Medical history (ever)
Non-menstrual bleeding 266/2734 (10%) 339/3326 (10%) 307/3325 (9%)
Sores or ulcers 294/2734 (11%) 357/3326 (11%) 342/3325 (10%)
Unusual genital discomfort 656/2734 (24%) 786/3326 (24%) 820/3325 (25%)
Unusual genital discharge 686/2734 (25%) 796/3326 (24%) 820/3325 (25%)
Pain during sex 140/2734 (5%) 181/3326 (5%) 163/3325 (5%)
Other genital disorders 22/2734 (1%) 21/3326 (1%) 28/3325 (1%)
Positive laboratory results
Chlamydia trachomatis 202/2698 (7%) 256/3293 (8%) 266/3295 (8%)
Neisseria gonorrhoeae 93/2698 (3%) 110/3293 (3%) 119/3295 (4%)
Herpes simplex virus type 2 seropositive 1622/2725 (60%) 2029/3312 (61%) 1982/3311 (60%)
Syphilis† 106/2726 (4%) 116/3300 (4%) 137/3304 (4%)
Trichomonas vaginalis 268/2723 (10%) 312/3314 (9%) 314/3311 (9%)
Behavioural
Eﬀ ective contraception‡ 1514/2732 (55%) 1850/3326 (56%) 1873/3325 (56%)
Sex acts in previous week
0 542/2732 (20%) 627/3326 (19%) 610/3325 (19%)
1 433/2732 (16%) 573/3326 (17%) 534/3325 (17%)
≥2 1754/2732 (64%) 2124/3326 (64%) 2178/3325 (64%)
Missing/unknown 3/2732 (<1%) 2/3326 (<1%) 3/3325 (<1%)
Partners in previous week (median [IQR]) 1 (1–1) 1 (1–1) 1 (1–1)
Condom use at last sex act 1500/2732 (55%) 1894/3326 (57%) 1826/3325 (55%)
Anal sex in previous 4 weeks 28/2732 (1%) 42/3326 (1%) 31/3325 (1%)
Data are n/n of participants with reported data (%) unless otherwise stated. *2% PRO2000 gel was discontinued Feb 14, 2008. †Active syphilis was deﬁ ned on the basis of 
rapid plasma reagin titre. ‡Sterilisation, intrauterine contraceptive device, or use of injected, implanted, or oral contraception.
Table 1: Baseline characteristics
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detection, or at the last HIV-1-negative test for patients 
who did not become infected.
We analysed the primary eﬃ  cacy endpoint as time-to-
event, and groups were compared by use of hazard ratios 
(HRs) relative to the placebo group, 95% CI, and p values, 
which were obtained by Cox proportional hazards 
regression and stratiﬁ ed by clinic. We analysed secondary 
eﬃ  cacy endpoints as binary outcomes by logistic 
regression, the proportion infected with HSV-2 at week 40 
and week 52 for those HSV-2 negative at baseline; and 
cross-sectional prevalence of N gonorrhoeae and 
C trachomatis for all patients tested at week 24.
All women with follow-up clinical data were included in 
the safety analyses. Safety endpoints were analysed as 
time-to-ﬁ rst-event and groups compared as for the eﬃ  cacy 
analysis. All analyses for the 2% PRO2000 group were 
undertaken with all three groups, and were censored when 
the 2% PRO2000 gel was discontinued on Feb 14, 2008. All 
statistical tests were two-sided and all analyses were done 
with Stata version 10.1.
This trial is registered at http://isrctn.org, number 
ISRCTN 64716212.
Role of the funding source
MDP301 was supported by the UK Department for 
International Development (DFID), the UK Medical 
Research Council (MRC), the European and Developing 
Countries Clinical Trials Partnership, and the International 
Partnership for Microbicides. The sponsors of the study 
had no role in study design, data collection, data analysis, 
data interpretation, or writing of the report. Endo 
Pharmaceuticals Solutions donated the study gels, provided 
regulatory support, and participated in design and 
management of the study. The corresponding author had 
full access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
Figure 1 shows the trial proﬁ le and table 1 shows patient 
characteristics at baseline. We screened women for HIV-1 
infection between September, 2005 and August, 2008, and 
enrolled 9404 participants; 19 of these participants enrolled 
twice, and data for their second enrolment were excluded 
from all analyses, including one seroconversion during the 
participant’s second enrolment. 2591 (95%) of 
2734 participants randomly assigned to the 2% PRO2000 
gel group were eligible for inclusion in the primary eﬃ  cacy 
analysis, 3156 (95%) of 3326 were eligible in the 0·5% 
PRO2000 gel group, and 3112 (94%) of 3325 were eligible 
in the placebo gel group.
Table 2 shows HIV-1 incidence in the 0·5% PRO2000 gel 
and placebo gel groups at study end, and for all gel groups 
at censoring on Feb 14, 2008. In the primary eﬃ  cacy 
analysis, incidence of HIV-1 did not diﬀ er between groups 
at discontinuation of 2% PRO2000 or study end (table 2). 
Equally, incidence of HIV-1 did not diﬀ er between groups 
in the second analysis that did not censor for pregnancy 
(table 2).
Gel eﬃ  cacy against HIV-1 transmission did not diﬀ er 
between centres (p=0·19 for interaction), or between 
consistent (HR 0·97, 95% CI 0·87–1·35, p=0·87) and 
inconsistent (1·17, 0·42–1·72, p=0·42) gel users (p=0·47 
for interaction). HIV-1 incidence did not diﬀ er between gel 
groups at weeks 24 or 40 (data not shown).
Table 3 shows analyses for secondary eﬃ  cacy endpoints. 
No diﬀ erences between groups were noted for data 
End of study Censored at 2% PRO2000 gel discontinuation, Feb 14, 2008
0·5% PRO2000 
(n=3326)
Placebo 
(n=3325)
2% PRO2000 
(n=2734)
0·5% PRO2000 
(n=2732)
Placebo 
(n=2722)
Primary eﬃ  cacy analysis*
Participants 3156 3112 2591 2587 2543
Woman-years of follow-up 2873 2836 1741 1732 1717
Seroconversions 130 123 82 67 67
Incidence† 4·5 (3·8–5·4) 4·3 (3·6–5·2) 4·7 (3·8–5·8) 3·9 (3·0–4·9) 3·9 (3·1–5·0)
Hazard ratio 1·05 (0·82–1·34) 1 1·21 (0·88–1·68) 0·99 (0·70–1·39) 1
p value 0·71 ·· 0·24 0·94 ··
Second eﬃ  cacy analysis‡
Participants 3156 3112 2591 2587 2543
Woman-years of follow-up 3133 3099 1847 1846 1832
Seroconversions 145 143 86 70 77
Incidence† 4·6 (3·9–5·4) 4·6 (3·9–5·4) 4·7 (3·8–5·8) 3·8 (3·0–4·8) 4·2 (3·4–5·3)
Hazard ratio 1·00 (0·79–1·26) 1 1·11 (0·82–1·51) 0·90 (0·65–1·24) 1
p value 0·99 ·· 0·50 0·53 ··
Data are n or n (95% CI) unless otherwise stated. ··=not applicable. *All enrolled participants, excluding those with HIV-1 infection at enrolment, those without follow-up data 
for HIV-1 infection, and censored at 52 weeks (plus 6 week window for ﬁ nal visit) or pregnancy. ‡Equivalent to primary eﬃ  cacy analysis, but not censored for pregnancy or at 
week 52. †Per 100 woman-years.
Table 2: Primary eﬃ  cacy outcome: HIV-1 incidence in the primary and secondary eﬃ  cacy analyses
Articles
1334 www.thelancet.com   Vol 376   October 16, 2010
obtained before discontinuation of 2% PRO2000 gel or at 
study end. For participants who were HSV-2-negative at 
randomisation, around 7% of the 0·5% PRO2000 and 
placebo groups were HSV-2 seropositive at week 40, and 
11–13% were HSV-2 seropositive at week 52. At week 24, 
around 3% of participants in each group were positive for 
N gonorrhoeae and around 6% were positive for C trachomatis 
(table 3). No diﬀ erences were reported between the three 
gel groups for these secondary eﬃ  cacy endpoints up to 
discontinuation of 2% PRO2000 (table 3).
Our main results are for the comparison of 0·5% 
PRO2000 and placebo. Of 6651 women allocated to 
0·5% PRO2000 and placebo groups, 5418 (81%) attended 
the week 52 visit, providing data for 2816 (85%) of the 
maximum possible woman-years for the 0·5% PRO2000 
group, and 5591 (83%) for the placebo group (data 
not shown).
Reported adherence did not diﬀ er between the three gel 
groups. Reported condom use at last sex act increased 
gradually with time, and was similar across gel groups but 
varied between centres (ﬁ gure 2). The mean percentage 
reported gel use at last sex act was 89% (95% CI 86–91) 
after enrolment. This percentage changed little during the 
trial, and did not diﬀ er between centres or between 
participants who used or did not use a condom (ﬁ gure 2). 
Reported gel use decreased during the study for participants 
Figure 2: Adherence to condom and gel use, overall and by research centre
(A) Reported condom use, with or without gel use. (B) Reported gel use, with or without condom use. (C) Reported gel use in unprotected sex (no condom used). 2391 participants were enrolled in 
Durban, South Africa; 2499 in Johannesburg, South Africa; 840 in Masaka, Uganda; 1146 in Mwanza, Tanzania; 1177 in Africa Centre, South Africa; and 1332 in Mazabuka, Zambia.
Percentage of 
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End of study Censored at 2% PRO2000 gel discontinuation, Feb 14, 2008
0·5% PRO2000 (n=3326) Placebo (n=3325) 2% PRO2000 (n=2734) 0·5% PRO2000 (n=2732) Placebo (n=2722)
Herpes simplex virus type 2 
Infection by week 40 59/890 (6·6%) 66/907 (7·3%) 18/395 (4·6%) 22/374 (5·9%) 22/380 (5·8%)
Odds ratio 0·90 (0·63–1·30) 1 0·78 (0·41–1·47) 1·01 (0·55–1·87) 1
p value 0·59 ·· 0·44 0·55 ··
Infection by week 52 109/919 (11·9%) 115/888 (13·0%) 34/297 (11·5%) 34/292 (11·6%) 32/284 (11·3%)
Odds ratio 0·90 (0·68–1·20) 1 1·01 (0·61–1·70) 1·04 (1·62–1·73) 1
p value 0·48 ·· 0·95 0·89 ··
Neisseria gonorrhoeae
Infection at week 24 (±4 weeks) 77/2674 (2·9%) 74/2597 (2·9%) 42/1613 (2·6%) 44/1632 (2·7%) 48/1550 (3·1%)
Odds ratio 1·01 (0·73–1·40) 1 0·85 (0·56–1·29) 0·88 (0·56–1·29) 1
p value 0·95 ·· 0·44 0·54 ··
Chlamydia trachomatis
Infection at week 24 (±4 weeks) 159/2674 (6·0%) 164/2597 (6·3%) 79/1611 (4·9%) 95/1632 (5·9%) 90/1570 (5·8%)
Odds ratio 0·94 (0·75–1·17) 1 0·82 (0·60–1·11) 0·98 (0·73–1·31) 1
p value 0·58 ·· 0·20 0·90 ··
Data are n/n (%) or n (95% CI) unless otherwise stated. ··=not applicable.
Table 3: Secondary eﬃ  cacy outcomes
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reporting sex acts without a condom in Durban and 
Johannesburg centres (South Africa), but this analysis was 
done on the basis of only 78 and 198 sex acts, respectively, 
at week 52.
181 (2%) women reported having anal sex in the previous 
4 weeks at one or more of four visits; most (>90%) of these 
reports were from the South African sites, where HIV-1 
incidence was 5·4 per 100 woman-years. Of these 
181 women, 11 seroconverted, giving an incidence of 
6·3 per 100 woman-years.
Table 4 summarises adverse events. No deaths or serious 
adverse events were regarded as related to study gels. Rates 
of primary safety events did not diﬀ er between the 0·5% 
PRO2000, 2% PRO2000, and placebo groups (table 4). 
1450 (16%) of 9154 participants with follow-up clinical data 
had at least one solicited local toxic event after enrolment; 
genital itching was most commonly reported. 595 (33%) of 
1796 participants with routine laboratory data experienced 
at least one systemic toxic event (most commonly high 
concentrations of aspartate aminotransferase or bilirubin). 
Rates for local and systemic toxic eﬀ ects were similar 
between all gel groups (data not shown). PRO2000 
concentrations were below the lower limit of quantiﬁ cation 
in all 1789 plasma specimens analysed.
For all participants enrolled, incidence of pregnancy was 
11·6 per 100 woman-years (95% CI 10·9–12·4), ranging 
from 8·2 to 17·2 between centres but much the same 
between the three gel groups (11·9 per 100 woman-years in 
0·5% PRO2000 and placebo groups at study end; and 
10·1 in 2% PRO2000 group, 11·3 in 0·5% PRO2000 group, 
and 10·9 in placebo group at discontinuation ).
Discussion
Despite high rates of reported adherence, 0·5% PRO2000 
and 2% PRO2000 were not eﬀ ective for prevention of 
vaginally acquired HIV-1 infection or other sexually 
transmitted infections. MDP301 was done to the highest 
international standard to support a licence application, if 
indicated. Alongside the clinical, laboratory, and data 
management procedures for which international 
guidelines exist, we integrated social science into the trial 
protocol to a high degree,19 and a commitment to active 
community engagement and liaison was made at all sites. 
Completion of this multidisciplinary and multicountry 
trial in resource restricted settings is testimony to the 
success of the MDP partnership.
Accurate incidence data for the target population are 
essential to ensure a phase 3 HIV-1 prevention trial is 
End of study Censored at 2% PRO2000 gel discontinuation Feb 14, 2008
0·5% PRO2000 (n=3326) Placebo (n=3325) 2% PRO2000 (n=2734) 0·5% PRO2000 (n=2732) Placebo (n=2722)
Attended at least one visit after 
enrolment
3258 3223 2571 2524 2511
Primary safety events* 163 137 92 99 85
Woman-years of follow-up 3349 3317 1956 1929 1911
Primary safety event (ﬁ rst) 154 128 88 96 80
Incidence† 4·6 (3·9–5·4) 3·9 (3·2–4·6) 4·5 (3·7–5·5) 5·0 (4·1–6·1) 4·2 (3·4–5·2)
Hazard ratio 1·18 (0·93–1·49) 1 1·05 (0·78–1·43) 1·19 (0·88–1·60) 1
p value 0·17 ·· 0·74 0·26 ··
Adverse events
Non-menstrual bleeding 551 (17%) 527 (16%) 320 (13%) 339 (13%) 318 (13%)
Ulcers (internal) 32 (1%) 38 (1%) 20 (1%) 22 (1%) 25 (1%)
Ulcers (external) 161 (5%) 157 (5%) 121 (5%) 111 (4%) 116 (5%)
Oedema (internal) 11 (<1%) 15 (<1%) 5 (<1%) 5 (<1%) 9 (<1%)
Oedema (external) 8 (<1%) 5 (<1%) 6 (<1%) 3 (<1%) 5 (<1%)
Erythema (internal) 201 (6%) 201 (6%) 134 (5%) 117 (5%) 122 (5%)
Erythema (external) 54 (2%) 35 (1%) 39 (2%) 32 (1%) 29 (1%)
Itching 349 (11%) 310 (10%) 214 (9%) 247 (10%) 232 (9%)
Burning 72 (2%) 56 (2%) 52 (2%) 53 (2%) 46 (2%)
Other genital events 379 (12%) 356 (11%) 232 (9%) 241 (10%) 239 (10%)
Other non-genital events 685 (21%) 631 (20%) 442 (18%) 435 (17%) 424 (17%)
Serious adverse events‡
Deaths 9 (<1%) 5 (<1%) 7 (<1%)§ 4 (<1%) 0
Other serious adverse events 142 (4%) 119 (4%) 86 (3%) 95 (3%) 75 (3%)
Data are n (%) or n (95% CI). ··=not applicable. *Deﬁ ned as adverse events of grade 3 or more reported any time after enrolment. For women with more than one event, 
the time-to-event analysis uses the ﬁ rst event only. †Per 100 woman-years. ‡Serious adverse events were death, an immediate threat to life, admission to hospital, 
disability, congenital abnormality, vaginal oedema with sloughing, profuse non-menstrual bleeding, and cervical or gynaecological cancer. §Two additional deaths were 
reported after Feb 14, 2008.
Table 4: Reported serious adverse events, selected genital adverse events, and primary safety events
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adequately powered.4 In cohort studies18 done before 
MDP301, weighted HIV-1 incidence rates were estimated 
to be 6·2 per 100 woman-years. Our power calculations 
were based on a conservative estimate of four per 
100 woman-years because HIV-1 incidence in the target 
populations was assumed to fall during the study, and 
might have become even lower than the estimate because 
of the more frequent visits with HIV-1 counselling and 
testing. This strategy was justiﬁ ed as the reported overall 
HIV-1 incidence in the placebo group was 4·5 per 
100 woman-years. Our power calculations allowed for a 
20% loss of woman-years by 52 weeks, but only 12% were 
lost, which could translate to approximately 22 unobserved 
sero conversions, and is a potential limitation of this study. 
However, even in the extreme case that all 22 were 
attributed to either PRO2000 or to placebo, this would not 
alter the overall result of the trial. Diligent promotion of 
eﬀ ective methods of contraception resulted in a loss of 
only 4% of woman-years from the primary eﬃ  cacy analysis 
because of pregnancy. Incidence of pregnancy was similar 
across the gel groups, justifying the modiﬁ cation to the 
protocol analysis to censor patients while pregnant. In 
October 2007, after a Trial Steering Committee review of 
masked data, recruitment targets were revised to ensure 
that there was 75–80% power to detect eﬃ  cacy at a lower 
rate (30–35% reduction).
Self-reported adherence has been high in all microbicide 
trials so far,2–6 but scepticism remains about reporting of 
adherence in the absence of a reliable biomarker. In 
MDP301, self-reported adherence was corroborated by the 
return of used applicators, and participants were asked at 
every visit, which provided more opportunity to report 
non-adherence, increasing the stringency of the deﬁ nition 
of consistent. Information was also obtained from 
725 women randomly selected to take part in a social 
science substudy. As well as the clinic interviews and gel 
returns, these women completed coital diaries and were 
interviewed in-depth about sexual behaviour.
Triangulation of data from all sources suggested that 
adherence was high,20 and qualitative data suggested that 
women and their partners enjoyed using the gel.23 There 
were no diﬀ erences in reported adherence between the 
three gel groups, justifying use of these data to deﬁ ne 
consistency for the prespeciﬁ ed sub group analysis.
We suggest several reasons why PRO2000 did not 
provide protection in women despite promising results in 
vitro and in challenge studies in animals, with 10 of 
14 macaques protected in one study.13 In early studies,24,25 
active drug was recoverable from cervicovaginal lavage 
several hours after insertion, suggesting that it was 
released from the formulation and not overly diluted by 
vaginal secretions. However, in a study26 in which 
cervicovaginal lavage samples were obtained from ten 
women who inserted 0·5% PRO2000 gel, signiﬁ cantly 
lower concentrations of PRO2000 were recovered after sex 
without a condom (median 14 μg/mL, IQR 3–27) than 
were reported in the absence of sex (28 μg/mL, 22–110, 
p=0·04). This diﬀ erence could result from drug 
redistribution, binding to semen, loss from leakage, or 
diﬃ  culty in assaying drug because of physical changes 
after interaction with semen.
Several HIV-1 transmissions could have been the result 
of unprotected anal intercourse, although reported anal 
sex on the case report form was very uncommon, 1% at 
enrolment and 2% ever in the trial. Most reports of anal 
sex were from the South African sites (marginally lower 
than 2%), where the overall HIV-1 incidence was high. 
Although qualitative data from interviews and focus 
groups suggest that the frequency of anal sex might have 
been under-reported to the clinics, we do not attribute the 
absence of eﬃ  cacy noted in this trial to it.
The rationale for including two concentrations was that 
the 2% concentration of PRO2000 might have resulted in 
local inﬂ ammation, which might have inadvertently 
facilitated HIV-1 transmission, oﬀ setting any potential 
gain in biological potency against HIV-1. Although there 
was no evidence of this eﬀ ect in histology or colposcopy 
investigations in the phase 1 and 2 studies, we postulated 
that symptoms and signs might emerge in a long phase 3 
trial with cumulative exposure in a large population. The 
absence of local toxic eﬀ ects with PRO2000 was reassuring; 
and the absence of systemic toxic eﬀ ects was expected and 
consistent with the failure to detect PRO2000 in plasma 
after extended use.
Seven diﬀ erent molecular candidates have been assessed 
in 13 phase 2b/3 microbicide trials. One trial6 was designed 
to inform a decision algorithm, but only four of the 
remaining 12 had adequate statistical power to detect the 
prespeciﬁ ed eﬀ ect of interest, which ranged from 
35% to 50% for various reasons, including early 
termination3 and lower-than-expected incidence.4 One of 
the four trials with suﬃ  cient statistical power, COL-1492,27 
reported a signiﬁ cant increase in HIV infections in women 
who used nonoynol-9 compared with placebo; two trials, 
including MDP301, reported no eﬀ ect.2 In July, 2010, 
CAPRISA 00428 reported a 39% (95% CI 6–60%) reduction 
in HIV incidence in women who used the antiretroviral 
tenofovir 1% formulated as a vaginal gel, compared with 
women who used placebo gel. Women were advised to 
administer gel before and after sex, and to use no more 
than two applicators every 24 h. Tenofovir acts speciﬁ cally 
to block HIV replication at the intracellular level and is 
much more potent in vitro than any of the non-antiretroviral 
candidate gels. CAPRISA provided the proof of concept 
for antiretroviral prophylaxis and for microbicides. 
Five trials assessing eﬀ ectiveness of antiretroviral pro-
phy laxis are in progress and will report in the next 4 years. 
These ﬁ ve trials will assess daily tenofovir-based regimens 
taken oral, although one, the VOICE trial, will also assess 
tenofovir 1% as a microbicide, administered daily. 
Investigators need to establish whether coitally depen dent 
dosing is eﬀ ective, ideally in non-South African 
populations, as there are hypothetical advantages 
associated with the lower systemic drug concentrations in 
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a coitally dependent dosing regimen (eg, fewer toxic eﬀ ects 
or lower risk of drug resistance emerging during 
breakthrough infections). 
MDP301 shows that licensing trials can be done in 
resource-scarce settings, and the self-reported quantitative 
data obtained in MDP301, supported by the return of the 
used applicators, and the quantitative and qualitative data 
obtained in the social-science substudy, reinforce the 
acceptability of microbicides as potential products for 
prevention of HIV-1 transmission. CAPRISA 00428 showed 
that microbicides can prevent HIV infection.
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